Epigenomics increases share capitalal
Epigenomics announces that the Company's Executive Board today with the approval of the Supervisory Board has resolved on an increase of the Company's share capital by up to EUR 828,504 from the authorized capital, thus raising up to EUR 4.136.720 in total gross proceeds. This capital increase follows a previous capital increase through which the strategic partner BioChain invested into the Company. The newly issued shares resulting from the envisagedcapital increase will be offered against contribution in cashin a private placementtoinstitutional investors in Europe and the U.S.. The preemptive rights of the shareholders will be excluded. The issue price has been set at EUR 4.993 per share andequalsthe volume-weighted average XETRA trading price duringthe last three trading days including the day of this announcement.
Following completion of the placement, the Supervisory and Executive Boards of the Company are going to resolve on the final amount of shares to be issued.
Epigenomics AG intends to use the net proceeds from the offering to finance its current operations and to build and strengthen the distribution capacities for its lead product Epi proColon®, a blood-based test for the detection of colorectal cancer.
Other news from the department business & finance
